US20090324776A1 - Cysteine granules and use thereof as bifidobacterium animalis lactis growth stimulants - Google Patents
Cysteine granules and use thereof as bifidobacterium animalis lactis growth stimulants Download PDFInfo
- Publication number
- US20090324776A1 US20090324776A1 US12/307,572 US30757207A US2009324776A1 US 20090324776 A1 US20090324776 A1 US 20090324776A1 US 30757207 A US30757207 A US 30757207A US 2009324776 A1 US2009324776 A1 US 2009324776A1
- Authority
- US
- United States
- Prior art keywords
- cysteine
- animalis lactis
- strain
- inoculum
- granules
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 241001134770 Bifidobacterium animalis Species 0.000 title claims abstract description 271
- 239000008187 granular material Substances 0.000 title claims abstract description 209
- 235000018417 cysteine Nutrition 0.000 title claims abstract description 141
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 title claims abstract description 139
- 229940118852 bifidobacterium animalis Drugs 0.000 title claims abstract description 22
- 239000000021 stimulant Substances 0.000 title description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims abstract description 364
- 239000002054 inoculum Substances 0.000 claims abstract description 131
- 239000004201 L-cysteine Substances 0.000 claims abstract description 99
- 235000013878 L-cysteine Nutrition 0.000 claims abstract description 99
- 235000013365 dairy product Nutrition 0.000 claims abstract description 90
- 239000000203 mixture Substances 0.000 claims abstract description 67
- 239000000758 substrate Substances 0.000 claims abstract description 64
- 235000021001 fermented dairy product Nutrition 0.000 claims abstract description 35
- 238000011081 inoculation Methods 0.000 claims abstract description 15
- 229960002433 cysteine Drugs 0.000 claims description 260
- 239000006041 probiotic Substances 0.000 claims description 76
- 235000018291 probiotics Nutrition 0.000 claims description 76
- 230000000529 probiotic effect Effects 0.000 claims description 72
- 241000894006 Bacteria Species 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 27
- 230000008569 process Effects 0.000 claims description 24
- 244000199885 Lactobacillus bulgaricus Species 0.000 claims description 21
- 230000004060 metabolic process Effects 0.000 claims description 16
- 229940024606 amino acid Drugs 0.000 claims description 10
- 235000001014 amino acid Nutrition 0.000 claims description 10
- 150000001413 amino acids Chemical class 0.000 claims description 10
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 claims description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 8
- 229960001305 cysteine hydrochloride Drugs 0.000 claims description 8
- 238000010257 thawing Methods 0.000 claims description 8
- 235000014048 cultured milk product Nutrition 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- 230000004936 stimulating effect Effects 0.000 claims description 6
- 230000002349 favourable effect Effects 0.000 claims description 5
- 229940041514 candida albicans extract Drugs 0.000 claims description 4
- 239000012138 yeast extract Substances 0.000 claims description 4
- 239000012298 atmosphere Substances 0.000 claims description 3
- 241000031670 Saccharopolyspora thermophila Species 0.000 claims 3
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 238000000855 fermentation Methods 0.000 description 59
- 230000004151 fermentation Effects 0.000 description 59
- 241000194020 Streptococcus thermophilus Species 0.000 description 28
- 235000015140 cultured milk Nutrition 0.000 description 25
- 238000004519 manufacturing process Methods 0.000 description 25
- 239000000243 solution Substances 0.000 description 25
- 235000013336 milk Nutrition 0.000 description 24
- 239000008267 milk Substances 0.000 description 24
- 210000004080 milk Anatomy 0.000 description 24
- 239000012190 activator Substances 0.000 description 21
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 description 19
- 238000003860 storage Methods 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 241000186000 Bifidobacterium Species 0.000 description 13
- 229910002092 carbon dioxide Inorganic materials 0.000 description 10
- 230000008901 benefit Effects 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 230000020477 pH reduction Effects 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 230000002378 acidificating effect Effects 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 241000894007 species Species 0.000 description 8
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 7
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 7
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- LJPYJRMMPVFEKR-UHFFFAOYSA-N prop-2-ynylurea Chemical compound NC(=O)NCC#C LJPYJRMMPVFEKR-UHFFFAOYSA-N 0.000 description 7
- 239000002253 acid Substances 0.000 description 6
- 230000002503 metabolic effect Effects 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 235000020183 skimmed milk Nutrition 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 239000003925 fat Substances 0.000 description 5
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000019634 flavors Nutrition 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000004962 physiological condition Effects 0.000 description 5
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 235000013618 yogurt Nutrition 0.000 description 4
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 3
- 240000001046 Lactobacillus acidophilus Species 0.000 description 3
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 3
- 244000199866 Lactobacillus casei Species 0.000 description 3
- 235000013958 Lactobacillus casei Nutrition 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 229960003067 cystine Drugs 0.000 description 3
- 230000002939 deleterious effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 3
- 229940017800 lactobacillus casei Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 241000186016 Bifidobacterium bifidum Species 0.000 description 2
- 241000186012 Bifidobacterium breve Species 0.000 description 2
- 241001608472 Bifidobacterium longum Species 0.000 description 2
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229920002444 Exopolysaccharide Polymers 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 240000002605 Lactobacillus helveticus Species 0.000 description 2
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 244000057717 Streptococcus lactis Species 0.000 description 2
- 235000014897 Streptococcus lactis Nutrition 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 229940002008 bifidobacterium bifidum Drugs 0.000 description 2
- 229940004120 bifidobacterium infantis Drugs 0.000 description 2
- 229940009291 bifidobacterium longum Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 150000001945 cysteines Chemical class 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000001339 gustatory effect Effects 0.000 description 2
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 229940039696 lactobacillus Drugs 0.000 description 2
- 229940054346 lactobacillus helveticus Drugs 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 238000009928 pasteurization Methods 0.000 description 2
- 230000003094 perturbing effect Effects 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- LOFGYQLYKBUNOM-DKWTVANSSA-N (2r)-2-amino-3-sulfanylpropanoic acid;chloric acid Chemical compound OCl(=O)=O.SC[C@H](N)C(O)=O LOFGYQLYKBUNOM-DKWTVANSSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical group CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- IFQSXNOEEPCSLW-DKWTVANSSA-N L-cysteine hydrochloride Chemical compound Cl.SC[C@H](N)C(O)=O IFQSXNOEEPCSLW-DKWTVANSSA-N 0.000 description 1
- QIJRTFXNRTXDIP-JIZZDEOASA-N L-cysteine hydrochloride hydrate Chemical group O.Cl.SC[C@H](N)C(O)=O QIJRTFXNRTXDIP-JIZZDEOASA-N 0.000 description 1
- 235000013960 Lactobacillus bulgaricus Nutrition 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- 241000194034 Lactococcus lactis subsp. cremoris Species 0.000 description 1
- 241000192132 Leuconostoc Species 0.000 description 1
- 244000172809 Leuconostoc cremoris Species 0.000 description 1
- 235000017632 Leuconostoc cremoris Nutrition 0.000 description 1
- 241000192129 Leuconostoc lactis Species 0.000 description 1
- 241001468194 Leuconostoc mesenteroides subsp. dextranicum Species 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 241000192001 Pediococcus Species 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- XOWVFANEOZMPKG-REOHCLBHSA-N S-nitroso-L-cysteine Chemical compound OC(=O)[C@@H](N)CSN=O XOWVFANEOZMPKG-REOHCLBHSA-N 0.000 description 1
- 235000014962 Streptococcus cremoris Nutrition 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- -1 chlorine ions Chemical class 0.000 description 1
- 230000003749 cleanliness Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical class CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229940004208 lactobacillus bulgaricus Drugs 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 235000019449 other food additives Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 229940066779 peptones Drugs 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000020201 recombined milk Nutrition 0.000 description 1
- 235000020122 reconstituted milk Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/13—Fermented milk preparations; Treatment using microorganisms or enzymes using additives
- A23C9/1322—Inorganic compounds; Minerals, including organic salts thereof, oligo-elements; Amino-acids, peptides, protein-hydrolysates or derivatives; Nucleic acids or derivatives; Yeast extract or autolysate; Vitamins; Antibiotics; Bacteriocins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to granules of cysteine and to their uses as growth stimulants for Bifidobacterium animalis ssp lactis.
- probiotic strains are represented by species which grow slowly on a dairy substrate (generation time 1 h to 2 h for Bifidobacterium ), while technological ferments derive from yoghurt ferments which grow rather more rapidly (generation time 15 min to 30 min for S. thermophilus and L. bulgaricus ).
- probiotic population is between 10 6 and 10 7 cfu/g of fermented product.
- the search for a compound which can stimulate the growth of a probiotic is based on an in-depth knowledge of the strain as regards its nutritional requirements and the capacity of the dairy substrate to fulfill them.
- the quantities of activator compounds which have to be used in order to provide stimulation and which satisfy the above constraints are generally very small as a proportion with respect to the dairy substrates.
- Such doses generally less than 100 mg/L
- the allowable tolerances are not compatible with the measurement systems and the modes of incorporation used to produce the dairy substrates, and so using such substances on an industrial scale is problematic.
- the present application proposes an improvement which is especially adapted to strains of Bifidobacterium animalis ssp lactis .
- the present application thus proposes an inoculum which does not suffer from the disadvantages of the prior art, and which overcomes the problem of simple, safe and effective activation and/or stimulation of B. animalis lactis during the industrial production of a fermented dairy product with a probiotic value which is intended for human consumption, and more particularly a fermented dairy product which, in addition to the fermentation carried out by the probiotic B. animalis lactis , involves the symbiotic fermentation of S. thermophilus ⁇ L. bulgaricus.
- the present invention relates to an improved inoculum of Bifidobacterium animalis ssp lactis , to the use of said inoculum, and to fermented dairy products obtained using said inoculum.
- the inoculum of the invention is particularly adapted for direct inoculation of at least one strain of B. animalis lactis into a dairy substrate, to transform said dairy substrate into a fermented dairy product which is suitable for human consumption, and more particularly into a fermented dairy product with a probiotic value containing at least one strain of B. animalis lactis.
- the inoculum comprises, as a mixture or in the collective or “kit of parts” form, frozen granules and/or (a) lyophilisate(s), in which are a particular L-cysteine and at least one strain of B. animalis lactis.
- the inventors have selected a particular form of cysteine, namely an L-cysteine which is in a form such that the granules and/or lyophilisate(s) produced from said cysteine have (once defrosted and/or re-dissolved) a pH which is at least 4.
- a suitable L-cysteine is the L-cysteine which is usually known as cysteine base (the formula for which in its reduced form is HSCH 2 CH(NH) 2 CO 2 H).
- cysteine is more effective than the other forms of cysteine which are usually used (generally, cysteine-HCl), in the form of cysteine hydrochloride monohydrate).
- the inventors have succeeded in producing an inoculum in the form of frozen granules and/or lyophilisate(s) which combine or integrate cells of B. animalis lactis and this particular form of L-cysteine, without in any way damaging the physiological condition and/or the metabolism of B. animalis lactis.
- At least one granule or lyophilisate of the inoculum contains both cells of B. animalis lactis and this particular form of L-cysteine.
- a portion of the granules or a lyophilisate contains the particular L-cysteine of the invention, and another portion of the granules or another lyophilisate contains cells of B. animalis lactis.
- the present invention thus proposes a combined or integrated inoculum of B. animalis lactis with a cysteine activator.
- the inoculum of the invention can produce a population of said at least one strain of B. animalis lactis (or, if there are several, said strains of B. animalis lactis ) which does not fall below 5 ⁇ 10 7 cfu, preferably not below 10 8 cfu, per gram of fermented product, after at least 20 days, preferably at least 30 days storage of said fermented product at a temperature in the range 4° C. to 11° C. (see FIGS. 8 and 9 ).
- the inoculum of the invention is particularly suitable for the production of fermented milk with a high probiotic value, since it can maintain very high levels of B. animalis lactis during storage of the product in refrigerated surroundings, and since the L-cysteine activator used is present in doses such that neither the S. thermophilus+L. bulgaricus symbiosis nor the organoleptic qualities of the fermented milk are negatively affected.
- FIG. 1 flow diagram for:
- FIG. 2 flow diagram for the production of integrated granules (cysteine-HCl+probiotic ferment(s)): Bifidobacterium animalis lactis strain I-2494 or strain BB12® ferment, formulated into integrated granules, containing both probiotic ferment and cysteine, the cysteine here being cysteine-HCl.
- FIG. 3 change in pH over time for a dairy mix inoculated with:
- FIG. 4 flow diagram for the production of integrated granules (cysteine base+probiotic ferment(s): Bifidobacterium animalis lactis strain I-2494 or strain BB12® ferment, formulated into integrated granules, containing both probiotic ferment and cysteine, the cysteine here being cysteine base.
- FIG. 5 change in pH over time for a dairy mix inoculated with:
- FIGS. 6 to 9 comparison of dairy mixes
- FIGS. 6 and 7 change of pH over time (in hours);
- FIGS. 8 and 9 change in biomass (cfu/mL) over time (in days) during storage of fermented dairy product at 10° C.;
- FIGS. 6 and 8 Bifidobacterium animalis lactis strain BB12® probiotic ferment:
- FIGS. 7 and 9 Bifidobacterium animalis lactis I-2494 probiotic ferment:
- lactic fermentation when reference is made to “lactic fermentation”, this pertains to acidifying lactic fermentation, which means acidification following the production of lactic acid which may be accompanied by the production of other acids, carbon dioxide and various substances such as exopolysaccharides (EPS) or aromatic substances, for example diacetyl and acetaldehyde.
- EPS exopolysaccharides
- aromatic substances for example diacetyl and acetaldehyde.
- lactic ferment means a micro-organism or a strain of live or viable micro-organisms which is capable of bringing about such acidifying lactic fermentation on a dairy substrate.
- milks has the meaning which is usually applied in the dairy industry, i.e. products which are intended for animal consumption, more particularly human consumption, and which are derived from acidifying lactic fermentation of a dairy substrate. Such products may contain secondary ingredients such as fruits, vegetables, sugars, flavorings, etc.
- fertilizer is thus reserved in the present application for the milk product prepared with a dairy substrate which has undergone a treatment which is at least equivalent to pasteurization, inoculated with micro-organisms belonging to a characteristic species or characteristic species of each product. Coagulation of “fermented milks” must not be accomplished by any means other than those resulting from the activity of the micro-organism employed.
- a “fermented milk” has not undergone any treatment which can remove a constituent element of the milk substrate employed, and in particular, coagulum has not been removed.
- a “fermented milk” may be supplemented with one or more flavor extracts, one or more natural flavors, as well as, with a limit of 30 per 100 by weight of finished product, one or more sugars and other food additives providing a particular taste, or even cereals.
- the quantity of free lactic acid contained in a fermented milk must not be less than 0.6 grams per 100 grams at the point of sale to the consumer, and the quantity of protein with respect to the milk portion must not be less than that of normal milk.
- dairy substrate as used in the present application means “milk” as the term is understood in the dairy industry, i.e. a substrate essentially containing milk and/or milk components, with a composition such that lactic fermentation of said dairy substrate by strain(s) of lactic bacteria such as S. thermophilus and/or L. bulgaricus results in a product which may be destined for human food and more particularly which can be designated a fermented milk.
- dairy substrate thus encompasses milk of animal origin in any form and in any compositional variation: skimmed or unskimmed milk, concentrated or non-concentrated milk, ultrafiltered or non-ultrafiltered milk, fresh milk or otherwise, powdered or non-powdered milk, reconstituted or non-reconstituted milk, recombined or non-recombined milk, milk enriched in milk constituents or otherwise, milk supplemented or not supplemented with processing agents or agents which enhance the quality of the finished product, such as taste agents, flavorings, sugars etc.
- a dairy substrate intended for the manufacture of fermented milks may comprise skimmed milk, cream and skimmed milk powder (see Example 1 below).
- the term “dairy substrate” does not, however, include in its scope the designation “culture medium”.
- culture medium envisages a medium intended to encourage and/or stimulate the growth of lactic bacteria, and thus to produce an inoculum of lactic bacteria
- the term “dairy substrate” envisages a medium which is intended to undergo transformation by fermentation, to produce a food intended for human consumption.
- many compounds which may be added to a culture medium to stimulate and/or to encourage the growth of lactic bacteria may not be added to a dairy substrate to obtain a fermented milk or yoghurt.
- lactic ferments include the following lactic bacteria:
- Lactic bacteria are defined as live lactic bacteria which, when consumed in sufficient quantities, have beneficial effects to health which extend beyond their basic nutritional value (official definition from the World Health Organization).
- Probiotic lactic bacteria comprise the following lactic bacteria in particular:
- Probiotic lactic bacteria are not simple food additives which can simply be added in bulk to the dairy product. They are live bacteria which bring about acidifying fermentation the metabolism of which is affected by the conditions to which they are subjected during manufacture of the fermented milk product, then subsequently during storage of the fermented milk product up to the eat-by date (EBD).
- EBD eat-by date
- ferment either bacterial or technical strain, as used here means a ferment, bacterium or strain which participates in the structure and/or texture of the fermented dairy product as opposed to a ferment, bacterium or strain with an essentially probiotic function.
- the strains known as technical strains are the strains of S. thermophilus and L. bulgaricus.
- the invention concerns an inoculum which is particularly adapted to direct inoculation of at least one strain of Bifidobacterium animalis ssp lactis into a dairy substrate, to transform said dairy substrate into a fermented dairy product which is adapted for human consumption and which has a probiotic value as well as to the uses of said inoculum in the context of the production of such dairy products.
- the inoculum of the invention is more particularly adapted to the production of a fermented dairy product which is obtained by fermentation of a dairy substrate by the probiotic B. animalis lactis and by S. thermophilus ⁇ L. bulgaricus symbiosis.
- a fermented dairy product which is obtained by fermentation of a dairy substrate by the probiotic B. animalis lactis and by S. thermophilus ⁇ L. bulgaricus symbiosis.
- Such a product thus contains at least one strain of S. thermophilus , at least one strain of L bulgaricus and at least one strain of B. animalis lactis in the live form.
- the inoculum of the invention comprises at least one strain of B. animalis lactis.
- the inoculum of the invention comprises a particular cysteine, namely L-cysteine, which is in a form such that the granules and/or lyophilisate(s) which are obtained using this form of L-cysteine are such that the pH of the solution obtained after:
- this pH does not exceed a pH of 8.
- an L-cysteine in a form such that it has a pH which is more than 4 when it is placed in solution.
- a solution containing 1.25 grams of this form of cysteine per 50 mL of H 2 O has a pH of 4.5 to 5.5.
- L-cysteine base (or L-cysteine in the base form).
- L-cysteine base In its reduced form, L-cysteine base has the formula HSCH 2 CH(NH) 2 CO 2 H.
- L-cysteine base is not cysteine-HCl: it is thus neither a hydrochloride of cysteine nor a cysteine hydrochloride monohydrate.
- This particular cysteine can be assimilated by B. animalis lactis and is an activator for the growth of B. animalis lactis on a dairy substrate.
- This particular cysteine is suitable for human consumption. It satisfies legislation relative to fermented dairy products intended for human consumption.
- This particular cysteine can also stimulate growth, or at least the metabolism of B. animalis lactis , without perturbing the metabolism of other non-probiotic lactic bacteria and in particular without perturbing the symbiotic lactic fermentation exercised by S. thermophilus and L. bulgaricus.
- this particular cysteine can produce an inoculum, termed integrated, which includes both said at least one strain of B. animalis lactis and cysteine in the same physical unit, without the growth, or at least the metabolism, of this strain of B. animalis lactis being negatively affected.
- the inoculum of the invention does not include cysteine in the acid form such as cysteine-HCl (L-cysteine hydrochloride with formula HSCH 2 CH(NH) 2 CO 2 H.HCl).
- cysteine-HCl L-cysteine hydrochloride with formula HSCH 2 CH(NH) 2 CO 2 H.HCl.
- the inoculum of the invention is in a particular physical form. It is in the form of frozen granules and/or lyophilisate(s).
- This particular form of inoculum is particularly suitable for direct inoculation.
- the choice of the particular cysteine mentioned above means that the inoculum can be manufactured with all of these features, and a particularly active inoculum can be obtained.
- the choice of the particular L-cysteine of the invention means that said at least one strain of B. animalis lactis and said cysteine can be mixed together to produce frozen granules and/or lyophilisate(s) which comprise both said strain of B. animalis lactis and said cysteine in the same granules and/or in the same lyophilisate without the growth, or at least the metabolism, of said strain of B. animalis lactis being negatively affected.
- cysteine in the acid form such as cysteine-HCl (hydrochloride of L-cysteine with formula HSCH 2 CH(NH) 2 CO 2 H.HCl) instead of and in place of L-cysteine base.
- the inventors thus propose a frozen granule or lyophilisate in which are found both cells of said at least one strain of B. animalis lactis and said particular L-cysteine.
- This frozen granule or lyophilisate may be qualified as an inoculum of B. animalis lactis with an integrated activator.
- This frozen granule or lyophilisate is a preferred embodiment of the invention.
- An alternative to the pathway of integrating the activator may consist of not combining the activator in the same granule or lyophilisate with the strain of B. animalis lactis , but producing distinct frozen granules or lyophilisates.
- inoculums are direct alternatives to the integrated frozen granules or lyophilisate in that they consist in combining together the means of the invention but in distinct physical forms.
- FIG. 1 shows an illustration of the mode of production of integrated granules in accordance with the invention and of the mode of production of combined granules in accordance with the invention.
- the invention thus results from a combination of selecting a particular cysteine (preferably L-cysteine base) and developing a particular physical form (frozen granules and/or lyophilisate(s)), which is specially adapted to direct inoculation.
- the inoculum of the invention is also specially adapted to stimulating the growth of strains of B. animalis lactis . It cannot be adapted to stimulating other species or genuses of probiotic bacteria.
- a growth activator In order to stimulate the growth of strains of B. animalis lactis , a growth activator must be available which exerts a positive effect on the growth, or at least on the metabolism, of B. animalis lactis without in any way exerting a negative or deleterious effect on the texture nor on the structure nor on the health-giving and gustatory quality of the fermented dairy product obtained.
- Each lactic bacterium employed does not necessarily have the same metabolism, and conditions favorable to one species or genus are not necessarily favorable to another species or another genus.
- This element is supplemented by the fact that lactic fermentation is constrained to a particular acidification kinetic/dynamic in order to be able to manufacture a good quality, safe fermented dairy product.
- fermented milks obtained by fermentation of S. thermophilus and L. bulgaricus and also by fermentation of the probiotic B. animalis lactis is particularly difficult as, in addition to the fermentation of B. animalis lactis , a symbiotic lactic fermentation must be carried out which involves at least one strain of Streptococcus thermophilus and at least one strain of Lactobacillus delbrueckii ssp bulgaricus.
- B. animalis lactis is a species which grows slowly on a dairy substrate (generation time of the order of 1 to 2 hours), while the technical ferments S. thermophilus and L. bulgaricus grow rapidly (generation time of the order of 15 to 30 min).
- the inoculum of the invention is specially designed not to exert a negative effect on the fermentation which could be carried out by lactic bacterial strains termed technical strains, and in particular on the symbiotic fermentation of Streptococcus thermophilus and Lactobacillus delbrueckii ssp bulgaricus.
- the inoculum of the invention is specially adapted for use in the context of producing a fermented milk which comprises at least one strain of B. animalis lactis as a probiotic strain and which is obtained by fermentation of a dairy substrate by at least one strain of Streptococcus thermophilus and at least one strain of Lactobacillus delbrueckii ssp bulgaricus in addition to the fermentation carried out by B. animalis lactis.
- the inoculum of the invention satisfies various criteria and can produce a fermented dairy product with a high probiotic value and which is of exceptional quality.
- the inoculum of the invention is optimized for the particularly complex problem posed by the symbiotic fermentation of S. thermophilus and L. bulgaricus in the presence of a fermentation of B. animalis lactis clearly does not prevent its use in less complex situations, such as that of fermentation of a dairy substrate which uses only one genus or species of lactic bacteria other than B. animalis lactis in addition to said at least one strain of B. animalis lactis or which uses only strains of B. animalis lactis.
- One advantage of the inoculum of the invention is that it can produce a population of said at least one strain of B. animalis lactis (or if there are several, said strains of B. animalis lactis ) which is substantially higher than that which would be obtained under the same conditions but using a conventional inoculum of the same strain of B. animalis lactis without a growth activator and is also substantially higher than that which would be obtained under the same conditions but using an inoculum from the same strain of B. animalis lactis and cysteine-HCl as a growth activator.
- the inoculum of the invention can thus produce a population of said at least one strain of B. animalis lactis (or, if there are several, said strains of B. animalis lactis ) which is at least 5 ⁇ 10 7 cfu per gram of fermented product at the end of fermentation, preferably at least 10 8 cfu per gram of fermented product at the end of fermentation.
- the inoculum of the invention has the advantage of being suitable for producing a population of said at least one strain of B. animalis lactis (or, if there are several, said strains of B. animalis lactis ) which does not fall below 5 ⁇ 10 7 cfu per gram of fermented product, after at least 20 days, preferably at least 30 days of storage of said fermented product at a temperature in the range 4° C. to 11° C., preferably at a temperature in the range 4° C. to 10° C., highly preferably at a temperature in the range 4° C. to 9° C.
- the inoculum of the invention has the advantage of being able to produce a population of said at least one strain of B. animalis lactis (or, if there are several, said strains of B. animalis lactis ) which does not fall below 10 8 cfu per gram of fermented product after at least 20 days, preferably at least 30 days of storage of said fermented product at a temperature in the range 4° C. to 11° C., preferably at a temperature in the range 4° C. to 10° C., and highly preferably at a temperature in the range 4° C. to 9° C.: see FIGS. 8 and 9 , showing that for at least 30 days of storage at 10° C., the population of B.
- animalis lactis in fermented milks ( S. thermophilus ⁇ L. bulgaricus+B. animalis lactis ) produced using an inoculum in accordance with the invention is maintained compared with reference fermented milks for which the population of B. animalis lactis fell rapidly from the 21 st day.
- Another advantage of the inoculum of the invention is that it is in a form which is suitable for use in an industrial context.
- the inoculum of the invention is in an improved form which means that it can be used in a particularly safe and easy manner in the context of industrial production of a fermented dairy product.
- the doses of growth activators and the accepted tolerances may sometimes be difficult to control as regards the systems for measurement and incorporation used to produce fermented dairy products in an industrial environment.
- an excess of activator while it is beneficial to the probiotic strain, is generally highly deleterious to the quality of the fermented dairy product obtained: it may result in a poor flavor (for example a sulfurous taste for cysteine added in excess), or it may exert negative or deleterious effects on the fermentation of technical strains (this is, for example, the case for S. thermophilus when an excess of cysteine is used).
- the control of the quantities of activator added is also important for sanitary reasons as this control limits human intervention and the amount of modification to and adaptation of industrial lines where cleanliness must be absolutely guaranteed. Controlling the quantities of activator added is also clearly of economic importance.
- the inoculum of the invention is very easy to use in an industrial context and the quantity of activator used can be controlled safely and easily.
- the inoculum of the invention is thus easier to use, and means that fermented dairy products with excellent textural, structural and flavor qualities can be manufactured in an industrial environment effectively and reliably and contain the probiotic B. animalis lactis in a particularly high dose.
- the inoculum of the invention is the result of a delicate compromise between:
- the inoculum of the invention satisfies these various aims.
- the inoculum of the invention comprises, as a mixture or in the form of a kit of parts:
- this pH does not exceed a pH of 8.
- a free L-cysteine is preferably selected which is in a form such that it has a pH which is over 4 when it is placed in solution.
- a solution containing 1.25 grams of this form of cysteine per 50 mL of H 2 O has a pH which is from 4.5 to 5.5.
- L-cysteine also known as L-cysteine base (or L-cysteine in the base form).
- L-cysteine base or L-cysteine in the base form.
- the formula of L-cysteine base is HSCH 2 CH(NH) 2 CO 2 H.
- L-cysteine in accordance with the invention and of cells of B. animalis lactis contained in the inoculum of the invention are distributed in solid physical structures, namely frozen granules and/or (a) lyophilisate(s).
- Said cysteine and said at least one strain of B. animalis lactis may be contained together in the same solid structure, or they may be present in distinct solid structures. These distinct solid structures may themselves be packaged separately but in a kit of parts, or they may be as a mixture.
- Said cysteine and said at least one strain of B. animalis lactis may thus be:
- all or part of said particular L-cysteine and the B. animalis lactis cells may be together in the same frozen granules or in the same lyophilisate.
- the inoculum of the invention then comprises at least one frozen granule and/or a lyophilisate, which contains both the particular L-cysteine of the invention and B. animalis lactis cells.
- all of the particular L-cysteine and B. animalis lactis cells contained in the inoculum are together in the same frozen granules or in the same lyophilisate.
- All or part of said particular L-cysteine of the invention and B. animalis lactis cells may be physically separated but collected into a kit of parts in distinct frozen granules and/or distinct lyophilisates.
- the inoculum of the invention then comprises:
- all of the particular L-cysteine of the invention and all of the B. animalis lactis cells contained in the inoculum may thus be contained in or be in the form of distinct granule(s) and/or distinct lyophilisate(s).
- the inoculum of the invention may thus comprise or be constituted by the following elements:
- the inoculum of the invention contains cysteine said to be in the free form (i.e., not bound to other amino acids via a peptide linkage) which results from a particular selection carried out by the inventors.
- Said cysteine in the free from is a free L-cysteine which, in addition, is in a form such that it can produce granules and/or lyophilisate(s) which are such that the pH of the solution obtained after:
- an L-cysteine is preferably selected which is in a form such that the pH of a solution constituted by 1 to 1.5 grams of said cysteine in 50 to 100 mL of H 2 O is at least 4.
- L-cysteine also known as L-cysteine base
- the formula for which in the reduced form is HSCH 2 CH(NH) 2 CO 2 H.
- cysteine-HCl cyste hydrochloride, or cysteine hydrochloride monohydrate
- none of the compounds used to manufacture the inoculum of the invention is in the hydrochloride form.
- L-cysteine of the invention which is contained in the inoculum of the invention is not a cysteine acid such as L-cysteine hydrochloride (HSCH 2 CH(NH) 2 CO 2 H.HCl) or L-cysteine hydrochloride monohydrate (HSCH 2 CH(NH) 2 CO 2 H.HCl.H 2 O).
- L-cysteine hydrochloride HSCH 2 CH(NH) 2 CO 2 H.HCl
- L-cysteine hydrochloride monohydrate HSCH 2 CH(NH) 2 CO 2 H.HCl.H 2 O
- L-cysteine hydrochloride monohydrate is not a particular cysteine in accordance with the invention, since a solution constituted by 1.0 g of L-cysteine hydrochloride monohydrate in 100 mL of H 2 O has a pH of 1.5 to 2.0.
- cysteines in the highly acidic form are cysteines in the form of salts such as L-cysteine hydrochloride or L-cysteine hydrochloride monohydrate.
- the ion or ions in this salt are not present in the frozen granules or lyophilisate.
- the presence of this ion or ions may thus occasionally constitute a marker for use of a cysteine which is combined with an acidic entity (which generally acts to increase the solubility of the cysteine). This is the case, for example, with the chloride ions contained in L-cysteine hydrochloride or L-cysteine hydrochloride monohydrate.
- cysteine of L-cysteine hydrochloride or L-cysteine hydrochloride monohydrate contained a large quantity of chloride (Cl) since L-cysteine hydrochloride monohydrate contains more than 19% chloride and that L-cysteine base generally contains less than 0.05%, more preferably less than 0.040%.
- the presence of a large quantity of chloride in the granule or lyophilisate may thus constitute an indirect marker of the use of a cysteine which is not a cysteine base.
- the form of cysteine used in an inoculum of the invention will generally provide less than 60 micrograms of chlorine ions per gram of granules with a dry matter content of 16-17%.
- the first criterion which is applicable is that of pH. Measuring the pH in fact constitutes a direct criterion for detecting the presence of a particular cysteine of the invention: the pH of the defrosted granules or the re-dissolved lyophilisate is then at least 4. It is generally at least 5, for example in the range 5 to 6.5. Preferably, said pH does not exceed a pH of 8.
- B. animalis lactis may thus be mixed into the cysteine solution without being subject to stress, and be formulated into frozen granules or lyophilisate which integrates cysteine and B. animalis lactis cells within a solid physical structure.
- the B. animalis lactis inoculum which results then contains cells of B. animalis lactis which are in a good physiological and/or metabolic condition, and which respond rapidly to the activation exerted by the cysteine.
- An “integrated” frozen granule or a lyophilisate of the invention which contains both cells of B. animalis lactis and a particular L-cysteine of the invention is thus a particularly improved B. animalis lactis inoculum in that it succeeds in integrating a B. animalis lactis activator into its structure without in any way altering the physiological and/or the metabolic state of the B. animalis lactis cells.
- L-cysteine of the invention means that granules and/or lyophilisates can be obtained which are more effective than granules and/or lyophilisate formulated from L-cysteine in the highly acidic form, such as L-cysteine hydrochloride, would be.
- this selection can integrate the cysteine in an effective manner into the same frozen granules or into the same lyophilisate.
- cysteine is used in a highly acidic form such as L-cysteine hydrochloride to formulate a frozen granule or a lyophilisate which comprises both cysteine-HCl and B. animalis lactis cells
- the resulting integrated granule or integrated lyophilisate is a less effective inoculum of B. animalis lactis compared with the same granule or lyophilisate obtained starting from the particular L-cysteine of the invention.
- the inoculum of the invention thus does not include a highly acidic cysteine and more particularly no L-cysteine hydrochloride and/or is not manufactured from such a cysteine.
- the inoculum of the invention is also not intended to include cystine.
- no cystine is added to the inoculum of the invention.
- traces of cystine may be found but they would, for example, be the results of oxidation of the cysteine contained in the inoculum.
- said particular L-cysteine of the invention is present in the inoculum in a quantity of:
- cysteine masses are calculated on the basis of a cysteine with formula HSCH 2 CH(NH) 2 CO 2 H.
- said particular L-cysteine of the invention is present in said inoculum in a quantity of:
- said particular L-cysteine of the invention is present in said inoculum in a quantity of 4.90 mg to 144 mg per 5 ⁇ 10 9 to 5 ⁇ 10 11 cfu of said at least one strain of B. animalis lactis.
- said particular L-cysteine of the invention is present in said inoculum in a quantity of 25 to 50 mg, more preferably 30 to 40 mg, still more preferably 31 to 39 mg, for example approximately 31, 32, 33, 34, 35, 36, 37, 38, 39 mg, highly preferably 35 to 37 mg, for example approximately 35, 36, 37 mg, and particularly preferably approximately 36.9 mg per 5 ⁇ 10 9 to 5 ⁇ 10 11 cfu of said at least one strain of B. animalis lactis.
- the number of cfu of B. animalis lactis is 5 ⁇ 10 9 to 5 ⁇ 10 11 cfu, more preferably 2 ⁇ 10 10 to 5 ⁇ 10 11 cfu of B. animalis lactis , highly preferably 2 ⁇ 10 10 to 1 ⁇ 10 11 cfu of B. animalis lactis , still more preferably 2 ⁇ 10 10 to 7 ⁇ 10 10 cfu of B. animalis lactis.
- 1 gram of granules in accordance with the invention which would comprise 16-17% dry matter (dry matter at 105° C. for at least 40 min), comprises 5 ⁇ 10 9 to 5 ⁇ 10 11 cfu of at least one strain of B. animalis lactis.
- 1 gram of granules in accordance with the invention which would comprise 16-17% dry matter (dry matter at 105° C. for at least 40 min) comprises 4.90 mg to 144 mg of said particular L-cysteine of the invention, preferably L-cysteine base.
- a quantity of 160 to 170 milligrams of a lyophilisate of the invention comprises 5 ⁇ 10 9 to 5 ⁇ 10 11 cfu of said at least one strain of B. animalis lactis.
- a quantity of 160 to 170 milligrams of a lyophilisate of the invention comprises 4.90 mg to 144 mg of said particular L-cysteine of the invention.
- cysteine contained in a liquid it is possible to use any technique which the skilled person deems appropriate, for example gas chromatography coupled with mass spectrometry, or high performance liquid chromatography coupled with fluorimetric detection. It is also possible to assay the cysteine using an amino acid analyzer such as the L-8800 High Speed Amino Acid Analyzer (Hitachi High Technologies).
- the inoculum of the invention does not include more than 0.5% (w/w) of yeast, yeast extract or yeast autolysate.
- the inoculum of the invention does not include more than 0.5% (w/w) of yeast, yeast extract or yeast autolysate. Highly preferably, said inoculum contains no yeast, yeast extract or yeast autolysate.
- the invention allows an inoculum of B. animalis lactis to be formulated with is highly active and which generates a population of B. animalis lactis which is maintained over time (during storage of the fermented milk product at refrigeration temperatures) without having to use a preservative in the inoculum and without having to add a preservative to the milk substrate or to the fermented milk product.
- the B. animalis lactis population is in the fermented milk product in a particular healthy physiological and/or metabolic condition, which means that it can be maintained at high levels.
- the inoculum of the invention comprises at least one strain of B. animalis lactis , for example, strain I-2494 or strain BB12® from Chr. Hansen.
- the inoculum of the invention may clearly comprise several strains of B. animalis lactis , for example strain I-2494 or strain BB12® from Chr. Hansen.
- the inoculum of the invention may also comprise at least one strain of lactic bacteria other than B. animalis lactis.
- Said at least one other strain of lactic bacteria may be present in the granules or lyophilisate(s) which contain the cells of B. animalis lactis and/or the particular L-cysteine of the invention.
- Said at least one other strain of lactic bacteria may be present in a physical structure which is distinct from that which contains the cells of B. animalis lactis .
- This distinct physical structure may, for example, be a solid structure, such as frozen granules or a lyophilisate which are mixed with the granules and/or lyophilisate(s) of B. animalis lactis and particular L-cysteine of the invention, or which are separated but in a kit of parts.
- This at least one other strain of lactic bacteria may, for example, be present in the form of frozen granules or a lyophilisate which are (is) distinct from the granules or lyophilisate(s) of B. animalis lactis and particular cysteine of the invention.
- This at least one other strain of lactic bacteria may be a strain of Bifidobacterium or a strain of another genus.
- This strain of a different genus may be a strain with a probiotic function, for example at least one strain selected from Lactobacillus acidophilus, Mactobacillus thamnosus, Lactobacillus casei.
- This strain of a different genus may be a strain with a technical function, such as S. thermophilus and/or L. bulgaricus.
- said inoculum of the invention comprises, in addition to the granule(s) and/or lyophilisate(s) of B. animalis lactis and particular L-cysteine, an inoculum of S. thermophilus and L. bulgaricus , for example in the form of frozen granule(s) and/or lyophilisate(s) adapted for direct inoculation.
- the inoculum of the invention comprises several strains other than B. animalis lactis , for example at least two, at least three, or at least four strains other than B. animalis lactis.
- said other strains are at least one strain of S. thermophilus (for example, strain I-1630 available from CNCM) and at least two strains of L bulgaricus (for example, strains I-1632 and I-1519 available from CNCM).
- Such an inoculum may be in the form of a mixture or a kit of parts collection of frozen granules and/or lyophilisate(s) containing B. animalis lactis and particular L-cysteine of the invention, and frozen granules and/or lyophilisate(s) containing S. thermophilus and/or L. bulgaricus .
- the ensemble is thus particularly suitable for direct inoculation of a dairy substrate with a view to transformation thereof by acidifying symbiotic S. thermophilus ⁇ L. bulgaricus lactic fermentation and by fermentation of B. animalis lactis to form a fermented milk with a high probiotic value and which maintains its high probiotic value during storage in a refrigerated medium.
- the present application is also relevant to an integrated granule of the invention per se and to an integrated lyophilisate of the invention per se.
- an integrated granule or lyophilisate in accordance with the invention comprises at least one strain of B. animalis lactis and the particular L-cysteine of the invention in the doses and/or proportions indicated.
- said granule or lyophilisate does not comprise cysteine in the highly acidic form such as L-cysteine monochlorate.
- the present application is thus relevant to a frozen granule which comprises at least one strain of B. animalis lactis , and to L-cysteine which is not bound to other amino acids by a peptide linkage, said L-cysteine being in a form such that the pH of the solution obtained after defrosting said granule(s) is at least 4, generally more than 5.
- the present application is thus relevant to a lyophilisate which comprises at least one strain of B. animalis lactis and L-cysteine which is not bonded to other amino acids by a peptide linkage, said L-cysteine being a cysteine in a form such that the pH of the solution obtained after re-dissolving said lyophilisate(s) in a proportion of 1 to 2 grams of lyophilisate(s) per 8 to 10 mL of H 2 O is at least 4, generally more than 5.
- the pH of the granule or lyophilisate is less than 8 (pH of the solution obtained after defrosting the granules or re-dissolving the lyophilisate).
- the invention is also relevant to uses of the inoculum of the invention.
- the invention is relevant to its uses in the context of acidifying lactic fermentation, and still more particularly to its uses in the context of manufacture of fermented milk products intended for human consumption.
- the invention is thus relevant to any process which uses at least one inoculum and/or at least one granule or lyophilisate in accordance with the invention.
- the invention envisages a process for stimulating the growth and/or metabolism of B. animalis lactis on a dairy substrate, which employs at least one inoculum and/or at least one granule and/or at least one lyophilisate in accordance with the invention.
- This stimulation process has the advantage of stimulating B. animalis lactis in a highly effective manner.
- the stimulation process of the invention can produce a population of B. animalis lactis the metabolism and/or growth of which can maintain live B. animalis lactis cells over time.
- said inoculum is added in the doses and/or proportions indicated above and/or described in the examples and figures below.
- said inoculum and/or granule and/or lyophilisate of the invention is added in quantities which supply to the dairy substrate:
- the inoculated substrate is preferably maintained under temperature and atmospheric conditions which are favorable to the metabolism of B. animalis lactis , for example 37° C. to 42° C. in a closed receptacle.
- the invention also envisages a process for producing a fermented dairy product, preferably a dairy product obtained by lactic fermentation, which lactic fermentation comprises at least symbiotic S. thermophilus ⁇ L. bulgaricus fermentation in addition to the fermentation carried out by B. animalis lactis.
- the process of the invention comprises using at least one inoculum and/or at least one granule and/or at least one lyophilisate in accordance with the invention.
- the fermented dairy product obtained is a fermented dairy product with a high probiotic value as it contains a large amount of B. animalis lactis and has a high content during storage in a refrigerated atmosphere.
- This production process has the advantage of activating and/or stimulating B. animalis lactis in a highly effective manner. It also has the advantage of not exerting a negative effect on the symbiosis of S. thermophilus and L. bulgaricus.
- the production process of the invention can produce a population of B. animalis lactis the metabolism and/or growth of which allows live cells of B. animalis lactis to be maintained over time.
- said inoculum is added in doses and/or proportions as indicated above and/or described in the following examples and figures.
- said inoculum and/or granule and/or lyophilisate of the invention is added in quantities which add to the dairy substrate:
- the inoculated substrate is preferably maintained under conditions of temperature and atmosphere which are favorable to the metabolism of B. animalis lactis , for example 37° C. to 42° C. in a closed receptacle.
- Said at least one strain of B. animalis lactis acts as a probiotic strain.
- said at least one strain of B. animalis lactis must also be capable of carrying out acidifying fermentation of the dairy substrate. Said at least one strain of B. animalis lactis is thus not simply added to the substrate or dairy product without allowing it to carry out acidifying fermentation as a simple additive would be.
- the process for producing the fermented parallel product may comprise using at least one strain other than said at least one strain of B. animalis lactis.
- Said other strain is preferably a strain of lactic bacteria.
- Said at least one other strain of lactic bacteria has the function of carrying out an acidifying lactic fermentation. It is thus inoculated into the dairy substrate in a manner such that it carries out acidifying lactic fermentation, i.e. at a moment and in quantities which allow it to carry out an acidifying lactic fermentation effectively.
- the fermentation process of the invention thus corresponds to mixed fermentation carried out by said at least one strain of lactic bacteria and by said at least one strain of B. animalis lactis , and not to a simple lactic fermentation process in which B. animalis lactis would be added as a simple additive without any detectable fermentation action.
- Said at least one strain of lactic bacteria and said at least one strain of B. animalis lactis are thus present together in the dairy substrate.
- the production process may thus not be a two-step process: adding said at least one strain of B. animalis lactis and any other strains of lactic bacteria may be carried out at the same time, or at least substantially at the same step of the process, namely at the start of the process, without having to wait and check that the fermentation undertaken by one of the strains has happened at a particular stage, in order to decide to add the other strain or strains.
- Fermentation of the dairy substrate is carried out at a temperature which is appropriate for the strains employed, and is generally carried out at a temperature in the range 36° C. to 42° C.
- Said fermentation is generally carried out until a pH in the range 4.8 to 4.2 is reached.
- the process for producing a fermented dairy product of the invention may also comprise one or more other steps, for example one or more other steps selected from conventional steps for producing the fermented dairy product concerned.
- the inoculum of the invention can thus produce a population of said at least one strain of B. animalis lactis (or, if there are several, said strains of B. animalis lactis ) which is at least 5 ⁇ 10 7 cfu per gram of fermented product at the end of fermentation, preferably at least 10 8 cfu per gram of fermented product at the end of fermentation.
- the inoculum of the invention has the advantage of being suitable for producing a population of said at least one strain of B. animalis lactis (or, if there are several, said strains of B. animalis lactis ) which does not fall below 5 ⁇ 10 7 cfu per gram of fermented product, after at least 20 days, preferably at least 30 days of storage of said fermented product at a temperature in the range 4° C. to 11° C., preferably at a temperature in the range 4° C. to 10° C., highly preferably at a temperature in the range 4° C. to 9° C.
- the inoculum of the invention has the advantage of being suitable for producing a population of said at least one strain of B. animalis lactis (or, if there are several, said strains of B. animalis lactis ) which does not fall below 10 8 cfu per gram of fermented product, after at least 20 days, preferably at least 30 days of storage of said fermented product at a temperature in the range 4° C. to 11° C., preferably at a temperature in the range 4° C. to 10° C., highly preferably at a temperature in the range 4° C. to 9° C.: see FIGS. 8 and 9 , illustrating maintenance at up to at least 30 days of storage at 10° C. of the population of B.
- animalis lactis in fermented milks produced using an inoculum in accordance with the invention S. thermophilus ⁇ L. bulgaricus+B. animalis lactis ) compared with reference fermented milks where the population of B. animalis lactis drops rapidly from the 21 st day.
- the term “masses of the fermented dairy product” means the mass of the lactic portion of the fermented dairy product.
- the present application is also relevant to the fermented dairy product per se.
- Such a product has a population of B. animalis lactis which maintains itself above that observed in prior art products, even after at least 20 days, preferably at least 30 days of storage of said fermented product at a temperature in the range 4° C. to 11° C., preferably at a temperature in the range 4° C. to 10° C., highly preferably at a temperature in the range 4° C. to 9° C.
- the present application is relevant to a fermented dairy product which can be obtained by lactic fermentation of a dairy substrate by at least one inoculum in accordance with the invention to a pH which is generally in the range 4.8 to 4.2.
- said inoculum is in the form of integrated frozen granules and/or an integrated lyophilisate of the invention (inoculum in which the particular L-cysteine is integrated with the B. animalis lactis ferment).
- said inoculum may also comprise at least one strain of S. thermophilus and/or at least one strain of L bulgaricus.
- CNCM denotes the Collection Nationale de Cultures de Microorganismes [National Collection of Microorganism Cultures] (Institut Pasteur; 25, rue du Dondel Roux; F-75724 PARIS CEDEX 15). Strains deposited with the CNCM carry a number commencing with “I-”, such as “I-2494” ( B. animalis lactis strain), “I-1630” ( S. thermophilus strain), “I-1632” or “I-1519” (strains of L. bulgaricus ).
- the term “comprising” includes the terms “consisting”, “constituted” as well as the terms “essentially consisting” and “essentially constituted”.
- Cysteine-HCl is not Suitable for the Manufacture of Granules Termed “Integrated” Granules which would Comprise both Cysteine and B. animalis lactis
- cysteine used was cysteine-HCl, which is normally used to provide cysteine because of its very good solubility (approximately 110 g per 100 g of H 2 O at 20° C.).
- Cysteine-HCl is the monohydrated hydrochloride of L-cysteine (or the monohydrated mono-hydrochloride of (R)-2-amino-3-mercaptopropionic acid). Its formula is C 3 H 7 NO 2 S.HCl.H 2 O (or L-cysteine.HCl.H 2 O). Its CAS number is 7048-04-6; it has a molar mass of 175.63.
- Cysteine-hydrochloride is commercially available, for example from Ajinomoto Aminoscience LLC, Raleigh N.C. 27610, USA.
- Frozen granules were produced by dropping the mixture into liquid nitrogen.
- a device comprising several syringe needles connected to a peristaltic pump via a tube was supplied with the mixture and the droplets formed at the needle ends were allowed to fall into an isothermal vessel filled with liquid nitrogen.
- the dairy mix was composed of the following ingredients: skimmed milk containing 0% of fat, cream containing 40% fat and skimmed milk powder (SMP) containing 33% protein.
- the standardization was checked using a MILKOSCAN FT 120® infrared detector from FOSS®.
- An example of the quantities of each ingredient required to obtain the target characteristics of milk is given below.
- the milk was then heated to a temperature of 50° C. to 60° C. to melt the fat globules properly. Once the temperature had been reached, the 10 liters were homogenized in a MICROFLUIDIZER®. This broke the fat globules by passing the milk in capillaries through a screen and at a pressure of 350 bar.
- a MEMMERT® water bath was prepared and adjusted to 103° C.
- the milk was transferred into 8 1 liter bottles, weighing the quantity placed in each bottle accurately.
- the bottles were immersed to the base of the neck in the water bath at 103° C. for 35 minutes then 10 minutes at 95° C. in the same water bath.
- the bottles were cooled in a continuous flow cold water bath then stored at 4° C. in a refrigerator for 12 to 24 hours until use.
- the milk bottles were removed from the refrigerator 45 minutes before inoculation of the ferments and placed in a water bath at the fermentation temperature (37° C.).
- Each inoculation was carried out in an amount of 0.2 grams of granules per liter of dairy mix.
- the bottles were re-immersed in the water bath (37° C.) and the change in pH was monitored over time (CINAC® apparatus from YSEBAERT®).
- the activity of the probiotic B. animalis lactis was greatly affected by adding cysteine-HCl to the granules of probiotic (increase of Ta).
- Cysteine-HCl is not a satisfactory source of cysteine for the manufacture of integrated granules, which comprise B. animalis lactis and cysteine in the same granules, and which are intended for the manufacture of fermented dairy products with a high probiotic value.
- the integrated solution ( B. animalis lactis granules+cysteine) cannot be used with cysteine-HCl as it renders the metabolic activity of the probiotic ferment inappropriate.
- the pH of a cysteine-HCl solution is less than 3.5; more particularly, the pH of a cysteine-HCl solution in a concentration of 1 g in 100 mL of H 2 O is 1.5 to 2.0, and that the probiotic B. animalis lactis is particularly sensitive to low pHs, even when the contact time is reduced.
- L-cysteine base (L-cysteine; C 3 H 7 NO 2 S; CAS number: 52-90-4; molar mass: 121.16) was selected instead of and in place of the cysteine-HCl.
- L-cysteine base is available from Ajinomoto Aminoscience LLC, Raleigh N.C. 27610, USA.
- the solubility of said cysteine base is 16 g per 100 g of H 2 O at 20° C.
- the pH of a solution containing 1.15 g of cysteine base per 50 mL of H 2 O is 4.5 to 5.5.
- a stock solution was prepared containing 160 g/L of cysteine base and 3 grams of this stock solution was mixed with 10 grams of B. animalis lactis ferment ( B. animalis lactis strain I-2494 or strain BB12®) which was formulated into frozen granules (I-2494 G4I Cys-base; and BB12 G4I Cys-base) as described in Example 1 above.
- B. animalis lactis ferment B. animalis lactis strain I-2494 or strain BB12®
- Reference granules I-2494 T and BB12 T were prepared using 3 grams of water instead of and in place of the cysteine base.
- FIG. 4 The manufacturing diagram for these granules is shown in FIG. 4 .
- the quantity of B. animalis lactis was approximately 2 ⁇ 10 10 cfu per gram of frozen G4I or G4 granules (I-2494 or BB12).
- the “integrated cysteine granules” process ( B. animalis lactis +cysteine granules) may be carried out with L-cysteine base, as B. animalis lactis retains its proper metabolic activity thereby.
- ferments termed technical ferments were also used; they were ferments of S. thermophilus and Lactobacillus delbrueckii ssp bulgaricus.
- the technical ferments used here corresponded to a mixture of three technical strains, namely the I-1630 strain of S. thermophilus and strains I-1632 and I-1519 of L. bulgaricus (strains available from CNCM).
- the technical ferments were supplied in the form of frozen granules.
- the technical ferments were inoculated into the dairy mix to an amount of approximately 1 ⁇ 10 6 cfu of S. thermophilus I-1630, and approximately 2.7 ⁇ 10 5 cfu of L bulgaricus (with 5% of strain I-1632 and 95% of strain I-1519) per gram of dairy substrate.
- the mixes were inoculated in an amount of 0.5 g/L of a mixture of granules (0.3 g/L of technical ferments and 0.2 g/L of granules of probiotic ferment B. animalis lactis ).
- the cysteine granules of the G4 mix were added so as to supply 7.5 mg/L of cysteine to the mix, i.e. a quantity of cysteine comparable to that provided by the G4I granules (calculated value 7.384 mg/L of cysteine; see Example 2 above).
- the bottle was cooled and stored at 20° C. Next, “breaking” of the bottle was carried out manually.
- Packaging into 125 mL pots was carried out manually and the closure was heat sealed with a DNV-100-25 PPV-A® heat sealer from FESTO®.
- the products were stored in a cold room at 10° C. throughout the duration of the test.
- the pH was measured during the fermentation period as well as the change in the biomass (cfu/mL as a function of number of days) during storage of the dairy product at 10° C.
- Tables 2 and 3 below show the values for several parameters of the acidification kinetics presented in FIGS. 6 and 7 .
- FIGS. 8 and 9 show the change in the cell population of the probiotic ferment B. animalis lactis BB12 in FIG. 8 and B. animalis lactis probiotic I-2494 in FIG. 9 during storage of the fermented dairy product ( S. thermophilus ⁇ L. bulgaricus symbiosis in addition to B. animalis lactis ) at a temperature of 10° C.
- L-cysteine clearly stimulates the cell population of probiotic and the integration of L-cysteine base was completely successful for each of the two strains of B. animalis lactis represented.
- the “integrated” G4I granules of L-cysteine base were also effective: they could lead to symbiotic lactic fermentation ( S. thermophilus+L. bulgaricus ) which was of at least as good a quality and could generate a cell population of B. animalis lactis probiotic ferment which was entirely comparable in size and which was maintained for the same length of time during storage of the fermented milk.
- the “integrated” G4I granules containing B. animalis lactis probiotic ferment and L-cysteine base and the “combined” G4 granules (granules of L-cysteine base distinct from the granules of probiotic) were much more effective than the reference system without cysteine (T granules): they led to symbiotic lactic fermentation ( S. thermophilus+L. bulgaricus ) at a quality which was at least comparable while generating a cell population of probiotic B. animalis lactis ferment which was much higher and which was maintained for a much longer period during storage of the fermented milk.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nutrition Science (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Dairy Products (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0606421A FR2903574B1 (fr) | 2006-07-13 | 2006-07-13 | Granules de cysteine et leurs utilisations a titre d'activateurs de croissance de bifidobacterium animalis lactis. |
FR0606421 | 2006-07-13 | ||
PCT/FR2007/000916 WO2008006949A1 (fr) | 2006-07-13 | 2007-06-01 | Granules de cysteine et leurs utilisations a titre d'activateurs de croissance de bifidobacterium animalis lactis |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2007/000916 A-371-Of-International WO2008006949A1 (fr) | 2006-07-13 | 2007-06-01 | Granules de cysteine et leurs utilisations a titre d'activateurs de croissance de bifidobacterium animalis lactis |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/840,515 Continuation US8828461B2 (en) | 2006-07-13 | 2013-03-15 | Cysteine granules and use thereof as Bifidobacterium animalis lactis growth stimulants |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090324776A1 true US20090324776A1 (en) | 2009-12-31 |
Family
ID=37726729
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/307,572 Abandoned US20090324776A1 (en) | 2006-07-13 | 2007-06-01 | Cysteine granules and use thereof as bifidobacterium animalis lactis growth stimulants |
US13/840,515 Active US8828461B2 (en) | 2006-07-13 | 2013-03-15 | Cysteine granules and use thereof as Bifidobacterium animalis lactis growth stimulants |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/840,515 Active US8828461B2 (en) | 2006-07-13 | 2013-03-15 | Cysteine granules and use thereof as Bifidobacterium animalis lactis growth stimulants |
Country Status (17)
Country | Link |
---|---|
US (2) | US20090324776A1 (da) |
EP (1) | EP2040560B1 (da) |
JP (1) | JP5265538B2 (da) |
CN (1) | CN101489400B (da) |
AT (1) | ATE465637T1 (da) |
BR (1) | BRPI0714162B1 (da) |
CA (1) | CA2655784C (da) |
CO (1) | CO6150095A2 (da) |
DE (1) | DE602007006196D1 (da) |
DK (1) | DK2040560T3 (da) |
FR (1) | FR2903574B1 (da) |
MX (1) | MX2009000491A (da) |
PL (1) | PL2040560T3 (da) |
RU (1) | RU2435843C2 (da) |
UA (1) | UA93556C2 (da) |
WO (1) | WO2008006949A1 (da) |
ZA (1) | ZA200900164B (da) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100272854A1 (en) * | 2006-10-02 | 2010-10-28 | Luc Terragno | Use of gum arabic for improving the growth and survival of bifidobacteria |
US10383921B2 (en) | 2013-08-13 | 2019-08-20 | President And Fellows Of Harvard College | Leveraging oxidative stress pathways in lactic acid bacteria to promote gut homeostasis |
WO2020091334A1 (ko) * | 2018-10-30 | 2020-05-07 | 씨제이제일제당 (주) | 유산균의 동결 보호를 위한 시스테인 또는 이의 염의 용도 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011172506A (ja) * | 2010-02-24 | 2011-09-08 | Glico Dairy Products Co Ltd | プロバイオティクス用のビフィドバクテリウム・アニマリス・サブスピーシーズ・ラクティス菌株及びこれを用いたプロバイオティクス乳酸菌発酵食品又はその他のプロバイオティクス経口食品。 |
EP2380446A1 (en) | 2010-04-22 | 2011-10-26 | Chr. Hansen A/S | Use of manganese for stimulation of growth of bifidobacteria |
CN103431042B (zh) * | 2013-08-28 | 2015-01-21 | 光明乳业股份有限公司 | 发酵乳基料、脱乳清风味发酵乳、原料组合物及制备方法 |
KR102124474B1 (ko) * | 2019-08-30 | 2020-06-19 | 주식회사 에이치이엠 | Pmas방법을 이용한 개인 맞춤형 장내 환경 개선 물질 스크리닝 방법 |
JP7301220B2 (ja) * | 2019-08-30 | 2023-06-30 | エイチイエム ファーマ インコーポレイテッド | Pmas方法を利用したパーソナライズ腸内環境改善物質スクリーニング方法 |
KR102227382B1 (ko) * | 2020-06-12 | 2021-03-15 | 주식회사 에이치이엠 | Pmas방법을 이용한 개인 맞춤형 장내 환경 개선 물질 스크리닝 방법 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010049132A1 (en) * | 2000-03-21 | 2001-12-06 | Borge Kringelum | Method for supply of starter cultures having a consistent quality |
US7008785B2 (en) * | 2000-07-04 | 2006-03-07 | Compagnie Gervais Danone | Micro-organisms with glycosylation modulating action of intestinal cell surface |
US20080181986A1 (en) * | 2005-07-13 | 2008-07-31 | Compagnie Gervais Danone | Fermented food products containing probiotic strains, and method for preparing same |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1271674A (en) * | 1968-07-09 | 1972-04-26 | Nisshin Flour Milling Co | Process and preparation for treating diarrhoea in pigs |
JPS61108385A (ja) * | 1984-11-01 | 1986-05-27 | Karupisu Shokuhin Kogyo Kk | ビフイズス菌末の製造法 |
JPS61265085A (ja) * | 1985-05-17 | 1986-11-22 | Kirin Brewery Co Ltd | 生菌保存安定性の良好なビフイズス菌培養物粉末の製造法 |
JPH02308754A (ja) * | 1989-05-24 | 1990-12-21 | Yakult Honsha Co Ltd | 乳発酵食品の製造法 |
JP3504365B2 (ja) * | 1995-02-01 | 2004-03-08 | 森永乳業株式会社 | 微生物保護剤及び該保護剤を用いた凍結又は凍結乾燥微生物の製造法 |
FR2801316B1 (fr) * | 1999-11-18 | 2005-03-25 | Rhodia Food | Procede de sechage des bacteries |
HU230800B1 (hu) * | 2000-05-25 | 2018-06-28 | Societe des Produits Nestlé S.A | Új probiotikumok hobbiállat-eledel kompozíciókhoz |
JP2003219862A (ja) * | 2002-01-29 | 2003-08-05 | Kyowa Hakko Kogyo Co Ltd | 凍結乾燥微生物の保存安定性を向上させる方法 |
FR2855182B1 (fr) * | 2003-05-19 | 2005-08-05 | Gervais Danone Sa | Nouveaux procede et inoculum pour fermentation lactique acidifiante |
-
2006
- 2006-07-13 FR FR0606421A patent/FR2903574B1/fr not_active Expired - Fee Related
-
2007
- 2007-06-01 RU RU2008149685/10A patent/RU2435843C2/ru active
- 2007-06-01 WO PCT/FR2007/000916 patent/WO2008006949A1/fr active Application Filing
- 2007-06-01 UA UAA200901094A patent/UA93556C2/ru unknown
- 2007-06-01 PL PL07788828T patent/PL2040560T3/pl unknown
- 2007-06-01 DE DE602007006196T patent/DE602007006196D1/de active Active
- 2007-06-01 AT AT07788828T patent/ATE465637T1/de not_active IP Right Cessation
- 2007-06-01 US US12/307,572 patent/US20090324776A1/en not_active Abandoned
- 2007-06-01 JP JP2009518912A patent/JP5265538B2/ja active Active
- 2007-06-01 MX MX2009000491A patent/MX2009000491A/es active IP Right Grant
- 2007-06-01 CA CA2655784A patent/CA2655784C/fr active Active
- 2007-06-01 EP EP07788828A patent/EP2040560B1/fr active Active
- 2007-06-01 BR BRPI0714162-9A patent/BRPI0714162B1/pt active IP Right Grant
- 2007-06-01 CN CN2007800265157A patent/CN101489400B/zh active Active
- 2007-06-01 DK DK07788828.7T patent/DK2040560T3/da active
-
2009
- 2009-01-08 ZA ZA200900164A patent/ZA200900164B/xx unknown
- 2009-02-05 CO CO09011069A patent/CO6150095A2/es unknown
-
2013
- 2013-03-15 US US13/840,515 patent/US8828461B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010049132A1 (en) * | 2000-03-21 | 2001-12-06 | Borge Kringelum | Method for supply of starter cultures having a consistent quality |
US7008785B2 (en) * | 2000-07-04 | 2006-03-07 | Compagnie Gervais Danone | Micro-organisms with glycosylation modulating action of intestinal cell surface |
US20080181986A1 (en) * | 2005-07-13 | 2008-07-31 | Compagnie Gervais Danone | Fermented food products containing probiotic strains, and method for preparing same |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100272854A1 (en) * | 2006-10-02 | 2010-10-28 | Luc Terragno | Use of gum arabic for improving the growth and survival of bifidobacteria |
US8945641B2 (en) | 2006-10-02 | 2015-02-03 | Compagnie Gervais Danone | Use of gum arabic for improving the growth and survival of bifidobacteria |
US10383921B2 (en) | 2013-08-13 | 2019-08-20 | President And Fellows Of Harvard College | Leveraging oxidative stress pathways in lactic acid bacteria to promote gut homeostasis |
WO2020091334A1 (ko) * | 2018-10-30 | 2020-05-07 | 씨제이제일제당 (주) | 유산균의 동결 보호를 위한 시스테인 또는 이의 염의 용도 |
Also Published As
Publication number | Publication date |
---|---|
BRPI0714162B1 (pt) | 2020-11-10 |
FR2903574B1 (fr) | 2008-09-05 |
CO6150095A2 (es) | 2010-04-20 |
WO2008006949A1 (fr) | 2008-01-17 |
CA2655784A1 (fr) | 2008-01-17 |
CN101489400B (zh) | 2013-08-07 |
BRPI0714162A2 (pt) | 2012-12-25 |
DE602007006196D1 (de) | 2010-06-10 |
EP2040560B1 (fr) | 2010-04-28 |
PL2040560T3 (pl) | 2010-10-29 |
RU2435843C2 (ru) | 2011-12-10 |
FR2903574A1 (fr) | 2008-01-18 |
JP5265538B2 (ja) | 2013-08-14 |
ZA200900164B (en) | 2009-12-30 |
JP2009542245A (ja) | 2009-12-03 |
DK2040560T3 (da) | 2010-08-16 |
CN101489400A (zh) | 2009-07-22 |
UA93556C2 (ru) | 2011-02-25 |
CA2655784C (fr) | 2014-10-21 |
US20130202739A1 (en) | 2013-08-08 |
RU2008149685A (ru) | 2010-08-20 |
EP2040560A1 (fr) | 2009-04-01 |
US8828461B2 (en) | 2014-09-09 |
MX2009000491A (es) | 2009-01-27 |
ATE465637T1 (de) | 2010-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8828461B2 (en) | Cysteine granules and use thereof as Bifidobacterium animalis lactis growth stimulants | |
Cruz et al. | Ice-cream as a probiotic food carrier | |
Shiby et al. | Fermented milks and milk products as functional foods—A review | |
US9474300B2 (en) | Fermented food products containing probiotic strains | |
EP2547214B1 (en) | Dried fermented dairy product containing a high density of living bifidobacteria | |
MXPA02001201A (es) | Bebidas y alimentos de leche fermentada y procedimiento para su elaboracion. | |
US8945641B2 (en) | Use of gum arabic for improving the growth and survival of bifidobacteria | |
BR112020010907A2 (pt) | composição láctea fermentada, processos para a preparação de uma composição láctea fermentada, inóculo e mistura | |
Madureira et al. | Sweet whey cheese matrices inoculated with the probiotic strain Lactobacillus paracasei LAFTI $^\circledR $ L26 | |
RU2720983C2 (ru) | Способы приготовления ферментированных продуктов, включающих бифидобактерии | |
ES2278329T3 (es) | Procedimiento e inoculo para fermentacion lactica acidificante. | |
Gursoy et al. | Survival of Bifidobacterium longum and its effect on physicochemical properties and sensorial attributes of white brined cheese | |
WO2023112941A1 (ja) | 発酵組成物、及びその製造方法 | |
AU2022417127A1 (en) | Fermentation composition and method for producing same | |
JP2022120417A (ja) | 香味が改善された発酵組成物、及びその製造方法 | |
Al-Slaihat et al. | DEVELOPING A LACTIC ACID BACTERIA | |
Madureira et al. | LAFTI L26 | |
Madureira et al. | Matrices fromagères de lactosérum doux inoculées avec la souche probiotique Lactobacillus paracasei LAFTI® L26 | |
MX2008008764A (en) | Fermented milk or yoghurt powder with a high density of lactic ferments |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: COMPAGNIE GERVAIS DANONE, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MARCHAL, LAURENT;DHOOSCHE, XAVIER;REEL/FRAME:022157/0497 Effective date: 20090113 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |